236 related articles for article (PubMed ID: 26515064)
1. A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv).
Tu C; Terraube V; Tam AS; Stochaj W; Fennell BJ; Lin L; Stahl M; LaVallie ER; Somers W; Finlay WJ; Mosyak L; Bard J; Cunningham O
J Biol Chem; 2016 Jan; 291(3):1267-76. PubMed ID: 26515064
[TBL] [Abstract][Full Text] [Related]
2. CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery.
Fennell BJ; McDonnell B; Tam AS; Chang L; Steven J; Broadbent ID; Gao H; Kieras E; Alley J; Luxenberg D; Edmonds J; Fitz LJ; Miao W; Whitters MJ; Medley QG; Guo YJ; Darmanin-Sheehan A; Autin B; Shúilleabháin DN; Cummins E; King A; Krebs MR; Grace C; Hickling TP; Boisvert A; Zhong X; McKenna M; Francis C; Olland S; Bloom L; Paulsen J; Somers W; Jensen A; Lin L; Finlay WJ; Cunningham O
MAbs; 2013; 5(6):882-95. PubMed ID: 23995618
[TBL] [Abstract][Full Text] [Related]
3. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
Choi BD; Gedeon PC; Kuan CT; Sanchez-Perez L; Archer GE; Bigner DD; Sampson JH
J Immunol Methods; 2013 Sep; 395(1-2):14-20. PubMed ID: 23806556
[TBL] [Abstract][Full Text] [Related]
4. Antibody VH and VL recombination using phage and ribosome display technologies reveals distinct structural routes to affinity improvements with VH-VL interface residues providing important structural diversity.
Groves MA; Amanuel L; Campbell JI; Rees DG; Sridharan S; Finch DK; Lowe DC; Vaughan TJ
MAbs; 2014; 6(1):236-45. PubMed ID: 24256948
[TBL] [Abstract][Full Text] [Related]
5. Seeking high-priority mutations enabling successful antibody-breeding: systematic analysis of a mutant that gained over 100-fold enhanced affinity.
Oyama H; Kiguchi Y; Morita I; Yamamoto C; Higashi Y; Taguchi M; Tagawa T; Enami Y; Takamine Y; Hasegawa H; Takeuchi A; Kobayashi N
Sci Rep; 2020 Mar; 10(1):4807. PubMed ID: 32179767
[TBL] [Abstract][Full Text] [Related]
6. Arginine mutations in antibody complementarity-determining regions display context-dependent affinity/specificity trade-offs.
Tiller KE; Li L; Kumar S; Julian MC; Garde S; Tessier PM
J Biol Chem; 2017 Oct; 292(40):16638-16652. PubMed ID: 28778924
[TBL] [Abstract][Full Text] [Related]
7. Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application.
Khantasup K; Chantima W; Sangma C; Poomputsa K; Dharakul T
Monoclon Antib Immunodiagn Immunother; 2015 Dec; 34(6):404-17. PubMed ID: 26683180
[TBL] [Abstract][Full Text] [Related]
8. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.
Finlay WJ; Cunningham O; Lambert MA; Darmanin-Sheehan A; Liu X; Fennell BJ; Mahon CM; Cummins E; Wade JM; O'Sullivan CM; Tan XY; Piche N; Pittman DD; Paulsen J; Tchistiakova L; Kodangattil S; Gill D; Hufton SE
J Mol Biol; 2009 May; 388(3):541-58. PubMed ID: 19285987
[TBL] [Abstract][Full Text] [Related]
9. Construction and molecular characterization of mouse single-chain variable fragment antibodies against Burkholderia mallei and Burkholderia pseudomallei.
Kim HS; Tsai S; Zou N; Lo SC; Wear DJ; Izadjoo MJ
J Immunol Methods; 2011 Feb; 365(1-2):101-9. PubMed ID: 21172353
[TBL] [Abstract][Full Text] [Related]
10. Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach.
Lehmann A; Wixted JH; Shapovalov MV; Roder H; Dunbrack RL; Robinson MK
MAbs; 2015; 7(6):1058-71. PubMed ID: 26337947
[TBL] [Abstract][Full Text] [Related]
11. Improvement of anti-Burkholderia mouse monoclonal antibody from various phage-displayed single-chain antibody libraries.
Kim HS; Lo SC; Wear DJ; Stojadinovic A; Weina PJ; Izadjoo MJ
J Immunol Methods; 2011 Sep; 372(1-2):146-61. PubMed ID: 21787781
[TBL] [Abstract][Full Text] [Related]
12. Cyclization of Single-Chain Fv Antibodies Markedly Suppressed Their Characteristic Aggregation Mediated by Inter-Chain VH-VL Interactions.
Yamauchi S; Kobashigawa Y; Fukuda N; Teramoto M; Toyota Y; Liu C; Ikeguchi Y; Sato T; Sato Y; Kimura H; Masuda T; Ohtsuki S; Noi K; Ogura T; Morioka H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31323851
[TBL] [Abstract][Full Text] [Related]
13. Unravelling enhancement of antibody fragment stability - Role of format structure and cysteine modification.
Ma H; Ó'Fágáin C; O'Kennedy R
J Immunol Methods; 2019 Jan; 464():57-63. PubMed ID: 30468735
[TBL] [Abstract][Full Text] [Related]
14. Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1.
Douthwaite JA; Sridharan S; Huntington C; Hammersley J; Marwood R; Hakulinen JK; Ek M; Sjögren T; Rider D; Privezentzev C; Seaman JC; Cariuk P; Knights V; Young J; Wilkinson T; Sleeman M; Finch DK; Lowe DC; Vaughan TJ
MAbs; 2015; 7(1):152-66. PubMed ID: 25484051
[TBL] [Abstract][Full Text] [Related]
15. Functional consequences of complementarity-determining region deactivation in a multifunctional anti-nucleic acid antibody.
Lee J; Kim HJ; Roh J; Seo Y; Kim M; Jun HR; Pham CD; Kwon MH
J Biol Chem; 2013 Dec; 288(50):35877-85. PubMed ID: 24155236
[TBL] [Abstract][Full Text] [Related]
16. De novo design of antibody complementarity determining regions binding a FLAG tetra-peptide.
Entzminger KC; Hyun JM; Pantazes RJ; Patterson-Orazem AC; Qerqez AN; Frye ZP; Hughes RA; Ellington AD; Lieberman RL; Maranas CD; Maynard JA
Sci Rep; 2017 Aug; 7(1):10295. PubMed ID: 28860479
[TBL] [Abstract][Full Text] [Related]
17. The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.
Giles I; Lambrianides N; Latchman D; Chen P; Chukwuocha R; Isenberg D; Rahman A
Arthritis Res Ther; 2005; 7(1):R47-56. PubMed ID: 15642142
[TBL] [Abstract][Full Text] [Related]
18. Cloning and characterization of a single-chain fragment of monoclonal antibody to ACE suitable for lung endothelial targeting.
Balyasnikova IV; Berestetskaya JV; Visintine DJ; Nesterovitch AB; Adamian L; Danilov SM
Microvasc Res; 2010 Dec; 80(3):355-64. PubMed ID: 20888351
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.
Zhang K; Geddie ML; Kohli N; Kornaga T; Kirpotin DB; Jiao Y; Rennard R; Drummond DC; Nielsen UB; Xu L; Lugovskoy AA
MAbs; 2015; 7(1):42-52. PubMed ID: 25484041
[TBL] [Abstract][Full Text] [Related]
20. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.
Schier R; McCall A; Adams GP; Marshall KW; Merritt H; Yim M; Crawford RS; Weiner LM; Marks C; Marks JD
J Mol Biol; 1996 Nov; 263(4):551-67. PubMed ID: 8918938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
